Andrew is Chief Commercial Officer of Chinook Therapeutics. He most recently served as President and CEO of Aimmune Therapeutics, where he led the organization’s integration into its new parent company, Nestlé Health Science, and expanded Aimmune’s portfolio and therapeutic focus beyond food allergy into disease states related to gastrointestinal conditions. Prior to his role as President and CEO, he served as Aimmune’s Chief Commercial Officer with a focus on building the company’s commercial in both the United States and Europe. Before joining Aimmune, Andrew spent 16 years at Eli Lilly and Company where he was responsible for Lilly’s U.S. insulin business as Vice President of U.S. Diabetes Connected Care and Insulins, after previously serving as Vice President of U.S. Diabetes Sales. His previous roles at Lilly include Vice President of the International Oncology business, General Manager of the Netherlands operation as well as positions of increasing responsibility in finance, marketing and sales in the U.S. and Europe. Andrew holds an M.B.A. from Harvard Business School and a Bachelor of Science in Mechanical Engineering from Purdue University.